KR840001836A - 생리활성 물질의 제법 - Google Patents
생리활성 물질의 제법 Download PDFInfo
- Publication number
- KR840001836A KR840001836A KR1019820004509A KR820004509A KR840001836A KR 840001836 A KR840001836 A KR 840001836A KR 1019820004509 A KR1019820004509 A KR 1019820004509A KR 820004509 A KR820004509 A KR 820004509A KR 840001836 A KR840001836 A KR 840001836A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- preparation
- bioactive substance
- axis represents
- cancer cells
- Prior art date
Links
- 239000000126 substance Substances 0.000 title description 3
- 230000000975 bioactive effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000519995 Stachys sylvatica Species 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 1에서 얻은 본 발명물질을 (a)는 정상시험쥐 태아세포(흑점)와 L-929의 암세포(백점)에, (b)는 정상 시험쥐 태아세포(흑점)와 HeLa-S3 의 암세포(백점)에 각각 시험관 안에서 작용시킨 경우의 세포장해를 나타낸다. 종축은 색소주입량(OD치)를 횡측은 농도를 표시한다. 실선은 혈청첨가배지를 사용한 경우를, 점설은 무혈청배지를 사용한 경우를 표시한다. 이것으로 본 발명물질이 암세포에만 특이적으로 작용하고, 또 종특이성(種特異性)이 없음을 알 수 있다. 제2도는 표준 단백질의 분자량과 SDS-PAGE에 있어서의 이동도와의 관계를 도시한다. 종축은 분자량을 횡축은 이동도를 나타낸다. a는 우혈청 알브민(BSA)을, b는 난백알브민(OVA)를 C는 기모트리프시노오겐을 표시한다. 흑점이 실시예 1에서 얻은 본 발명 물질의 위치이다. 이것에 의하여 본 발명 물질의 분자량을 알 수 있다. 제3도는 실시예 1에서 얻은 본 발명 물질의 Sephacryl-S 200에 의한 겔 여과 패턴이다. 종축은 세포의 사망율을, 횡축은 프랙션의 번호(1ml/tube)를 나타낸다.
Claims (1)
- 동물유래세포 또는 그들의 융합 세포를 배양하고 그 배양액을 정제하는 것을 특징으로 하는 암세포에만 특이적으로 작용하고 정상세포에는 작용하지 않는 항종양활성을 가지는 생리활성물질의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57021562A JPS58138383A (ja) | 1982-02-13 | 1982-02-13 | 生理活性物質の製法 |
JP21562 | 1982-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR840001836A true KR840001836A (ko) | 1984-06-07 |
Family
ID=12058451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019820004509A KR840001836A (ko) | 1982-02-13 | 1982-10-07 | 생리활성 물질의 제법 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0087087A3 (ko) |
JP (1) | JPS58138383A (ko) |
KR (1) | KR840001836A (ko) |
CA (1) | CA1201079A (ko) |
ES (1) | ES519737A0 (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5933223A (ja) * | 1982-08-20 | 1984-02-23 | Koken Kk | 人の悪性腫瘍細胞増殖抑制剤 |
JPS59162889A (ja) * | 1983-03-07 | 1984-09-13 | Koken Kk | 人の悪性腫瘍細胞の増殖抑制剤の製造方法 |
JPS59204122A (ja) * | 1983-05-06 | 1984-11-19 | Koken Kk | 人の悪性腫瘍細胞増殖抑制剤の製造方法 |
JPH088873B2 (ja) * | 1983-07-28 | 1996-01-31 | 大日本製薬株式会社 | ヒト癌壊死因子の製造法 |
JPS6028931A (ja) * | 1983-07-28 | 1985-02-14 | Koken Kk | ヒト腎細胞癌由来樹立株細胞の増殖抑制剤の濃縮方法 |
JPS6028930A (ja) * | 1983-07-28 | 1985-02-14 | Koken Kk | 人の癌由来細胞の増殖抑制剤の精製方法 |
JPS6043386A (ja) * | 1983-08-20 | 1985-03-07 | Koken Kk | ヒト腎細胞癌由来樹立株細胞の増殖抑制剤の製造方法 |
US5683688A (en) * | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
US4959457A (en) * | 1984-05-31 | 1990-09-25 | Genentech, Inc. | Anti-lymphotoxin |
US6686455B1 (en) | 1984-07-05 | 2004-02-03 | Genentech, Inc. | Tumor necrosis factor |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
JPS6127923A (ja) * | 1984-07-17 | 1986-02-07 | Denichi Mizuno | ヒト腫瘍壊死因子の製造法 |
IL73883A (en) † | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
JPS61155330A (ja) * | 1984-12-28 | 1986-07-15 | Denichi Mizuno | 蛋白質標品 |
JPS6255087A (ja) * | 1985-03-25 | 1987-03-10 | シタス オンコロジー コーポレイション | 融合蛋白質をコ−ドする組換dna配列 |
GB2245415A (en) * | 1990-06-22 | 1992-01-02 | Philips Electronic Associated | Infrared detector with a getter |
US9416086B2 (en) * | 2010-11-12 | 2016-08-16 | Eastman Chemical Company | Processes for purification of acid solutions |
US9415366B2 (en) * | 2012-12-31 | 2016-08-16 | Eastman Chemical Company | Systems and methods for processing variable acetyl streams |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3865689A (en) * | 1972-11-09 | 1975-02-11 | Hoffmann La Roche | Method of producing carcinoembryonic antigens |
US4195017A (en) * | 1975-02-25 | 1980-03-25 | Samuel Bogoch | Malignin, derived from brain tumor cells, complexes and polypeptides thereof |
FR2302747B1 (fr) * | 1975-03-03 | 1978-09-22 | Inst Nat Sante Rech Med | Procede d'obtention, a partir de macrophages de mammiferes, d'un produit therapeutique actif, notamment, a l'egard des cellules tumorales humaines et produit therapeutique ainsi obtenu |
DE2600442A1 (de) * | 1976-01-08 | 1977-07-14 | Karl Dr Med Theurer | Herstellung von biologischen arzneimitteln gegen maligne tumoren und blutkrankheiten aus zell- bzw. gewebekulturen |
DE2619715A1 (de) * | 1976-05-04 | 1977-11-24 | Max Planck Gesellschaft | Tumor-antigen und verfahren zu dessen herstellung |
US4059486A (en) * | 1976-11-03 | 1977-11-22 | Monsanto Company | Cell culture process |
US4228236A (en) * | 1978-05-15 | 1980-10-14 | Northwestern University | Process of producing carcinoembryonic antigen |
-
1982
- 1982-02-13 JP JP57021562A patent/JPS58138383A/ja active Pending
- 1982-10-07 KR KR1019820004509A patent/KR840001836A/ko unknown
-
1983
- 1983-02-08 CA CA000421104A patent/CA1201079A/en not_active Expired
- 1983-02-11 EP EP83101339A patent/EP0087087A3/en not_active Withdrawn
- 1983-02-11 ES ES519737A patent/ES519737A0/es active Granted
Also Published As
Publication number | Publication date |
---|---|
ES8403157A1 (es) | 1984-03-01 |
JPS58138383A (ja) | 1983-08-17 |
EP0087087A3 (en) | 1983-10-19 |
EP0087087A2 (en) | 1983-08-31 |
CA1201079A (en) | 1986-02-25 |
ES519737A0 (es) | 1984-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR840001836A (ko) | 생리활성 물질의 제법 | |
KR910015309A (ko) | 종양괴사인자(tnf) 억제제 및 그 제조방법 | |
ATE153858T1 (de) | Ligand für das neu-gen-produkt | |
FR2389637A1 (ko) | ||
DK0532525T3 (da) | Nye protein-polykationkonjugater | |
IT1207992B (it) | Derivati glicosilati dell'insulina. | |
IT8567140A1 (it) | Procedimento perfezionato per la produzione di proteine, particolarmente anticorpi, con l'impiego di mezzi ipertonici, e mezzo ipertonico per l'attuazione di tale procedimento. | |
KR900002795A (ko) | 하이브리드 단백질c 작제물 및 그들의 제조방법 | |
FR2445338A1 (fr) | Preparation de glycoproteine isolee d'enveloppes d'onco-rna virus et vaccins qui la contiennent | |
DE3884680D1 (de) | Äusseres Membranprotein F von Pseudomonas aeruginosa. | |
FR2573765B1 (fr) | Procede pour la synthese de peptides | |
Shabanowitz et al. | Two-dimensional electrophoresis of proteins in principal cells, spermatozoa, and fluid associated with the rat epididymis | |
DK0383599T3 (da) | Protein-anticancermiddel | |
FR2360562A1 (fr) | Nouveaux hexapeptides cycliques utiles pour augmenter l'efficacite des aliments, et leur procede de preparation | |
Rikihisa et al. | Taenia taeniaeformis: characterization of larval metabolic products and growth of host gastric cells in vitro | |
KR840002657A (ko) | 인터페론 조성물의 제조방법 | |
Hayase et al. | Microheterogeneity of N-acetyl-β-d-hexosaminidase of bull epididymis | |
Raam et al. | The Presence of J-Chains in the Intracellular Fluid of IgM-Secreting Murine Tumor Cells | |
KR890008166A (ko) | 융합 단백질의 선택적 분해 방법 | |
BE819319A (fr) | Nouveaux derives d'acide carbonique de 2-mercapto-4,5-dichlorothioazole. | |
ES2082140T3 (es) | Procedimiento para obtener proteina celular con actividad anti-hiv. | |
KR890003944A (ko) | 인간/인간 하이브리도마 배양용 무혈청배지 | |
KR890701733A (ko) | 신규 인체 조직형 플리스미노겐 활성제 변이체 | |
ROBBOY et al. | Zone electrophoresis and prolactin activity of rat adenohypophysis cultivated in vitro | |
KR890017268A (ko) | 항종양 활성을 갖는 단백질 |